Прегледај по Аутор "Lukic, Ruzica"

Сада се приказује 1 - 3 од 3
  • Сличица
    Ставка
    Increased systemic sST2 in patients with end stage renal disease contributes to milder liver damage during HCV infection
    (2020) Lukic, Ruzica; Cupic, Majа; Gajovic, Nevena; Jurisevic, Milena; Mijailovic, Zeljko; Davidovic, Bojana; Kujundžic, Bojan; Joksimovic, Bojan; Arsenijevic, Nebojša; Jovanovic, Ivan
    Introduction: Hepatitis C Virus (HCV) is the leading cause of chronic liver disease and is a serious global health problem. Hepatitis C infection is highly prevalent in patients with end stage renal disease (ESRD), due to frequent exposure to blood and blood products, nosocomial transmission of HCV, and prolong hemodialysis duration. The aim of the study was to evaluate the influence of IL-33/ST2 signaling pathway on severity of the liver disease in ESRD HCV+ patients. Methodology: Blood samples from patients with end stage renal disease (ESRD) and hepatitis C infection (HCV), 20 patients with HCV infection, 20 patients with ESRD and 20 healthy control donor patients were taken for the examination of biochemical parameters, for the determination of the serum cytokine concentration, and for the molecular diagnostics of HCV. Results: Systemic sST2 positively correlated with serum level of urea and creatinine, respectively. Serum sST2 was significantly increased in ESRD HCV+ patients in comparison to HCV+ group. sST2/IL-1, sST2/IL-4 and sST2/IL-23 ratios were significantly increased in serum of ESRD HCV+ patients in comparison to HCV+ patients. Significantly higher systemic level of sST2 and sST2/IL-1 and sST2/IL-4 ratios were measured in ESRD patients compared to non-ESRD patients. Conclusion: These results suggested that elevated level sST2, as the consequence of renal failure, causes less destruction of liver in HCV infection
  • Сличица
    Ставка
    MECHANISMS OF INTRACELLULAR CHLAMYDIAE SURVIVAL
    (University of Kragujevac, Faculty of Science, 2016) Lukic, Ruzica; Lukovic, Bojana; Gajovic, Nevena; Prljic, Slava; Djukic, Slobodanka
    Chlamydiae are Gram-negative, non-motile, obligate intracellular, and spherically shaped bacteria with a diameter of 0.2-1.5 μm. Chlamydiae are present in several diff erent morphological forms: the elementary body, the reticular body, and in the last several years, there has been the observation of a third form known as the persistent or atypical form. Th e intracellular localization of Chlamydia provides a unique replication cycle that occurs inside a membrane-surrounded vacuole in the host cell cytoplasm and is signifi cantly diff erent from the method of multiplication of other microorganisms. Chlamydiae are capable of manipulating diff erent signalling pathways inside the infected cell, thus avoiding the host immune response. Th is ensures intracellular multiplication, survival, and long-term persistence of Chlamydiae. Th ere are two basic means of achieving this persistence: inhibition of apoptosis and manipulation of NF-κB (nuclear factor kappa B)-mediated signals in the host.
  • Сличица
    Ставка
    Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients
    (Hindawi, 2017) Lukic, Ruzica; Gajovic, Nevena; Jovanovic, Ivan; Jurisevic, Milena; Mijailovic, Zeljko; Maric, Veljko; Popovska Jovicic, Biljana; Arsenijevic, Nebojsa
    Hepatitis C virus infection (HCV), one of the greatest causes of liver disease, is a frequent complication in patients with end-stage renal disease (ESRD) on dialysis. ESRD is defined as decreased glomerular filtration and also accompanied by impaired function of the immune system. Galectin-3 is a β-galactoside-binding lectin, involved in various biological processes including pathogenesis of chronic renal disease. The aim of our study was to estimate disease severity in ESRD HCV+ patients and analyze the serum concentrations of IL-1β, IL-4, IL-23, and IL-6; anti-HCV antibodies; and galectin-3. Also, we attempted to determine potential correlation between galectin-3 level and parameters of disease severity ALT and AST. Our results showed decreased levels of ALT and AST (p = 0 00), demonstrating less liver destruction in ESRD HCV+ patients in comparison to HCV+ patients. Increased levels of IL-6 (p = 0 03) implicate a hepatoprotective role of IL-6 in these patients. Also, level of galectin-3 (p = 0 00) in the serum of ESRD HCV+ patients was higher than that of HCV+ patients. This alteration was accompanied with negative correlation between galectin-3 and AST and ALT, respectively (p = 0 029; p = 0 033). The presence of increased systemic levels of IL-6 and Gal-3 in ESRD HCV+ patients may be an attempt to counteract or limit ongoing proinflammatory processes and to downregulate chronic inflammation, suggesting the new aspects of HCV infection in ESRD patients.